Introduction:
Coronavirus Disease 2019 (COVID-19), a respiratory virus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first discovered in Wuhan, China in December 2019 after several citizens developed symptoms of atypical pneumonia. The novel coronavirus was quick to spread throughout China and the world, research is still developing regarding its transmission and pathophysiology. On January 19, 2020 the first confirmed case of COVID-19 was documented in the United States in Washington State1 and in March 2020 the World Health Organization (WHO) declared COVID-19 a worldwide pandemic.2
As more individuals have become infected with COVID-19, more information has surfaced regarding symptomatology and associated lab abnormalities. One association that is seen in varying degree is transaminitis in COVID-19 positive patients.3 Currently, there is limited literature describing how transaminitis may be an important predictor of clinical outcomes in pregnant patients diagnosed with COVID-19. Additionally, patients who experience these laboratory abnormalities often begin to experience deterioration in their clinical status suggested by an increase in oxygen requirement, increasing respiratory rate, need for intubation, need for urgent delivery and ICU admission.4
The purpose of this retrospective case series is to better understand the relationship between transaminitis and maternal and neonatal outcomes in pregnant patients infected with COVID-19. Establishing an association between these factors can provide physicians with insight into the predictive power of these laboratory abnormalities for clinical disease progression.